Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.



Aindrilla S. Duttagupta*, Kisan R. Jadhav and Vilasrao J. Kadam


Gliclazide is a potential second generation oral hypoglycemic agent, which belongs to BCS class II drugs having low solubility and high permeability. It has log P value of 2.6, pKa of 5.8, molecular weight of 323.42, and has poor and variable oral bioavailability. The GI absorption rate of gliclazide is very slow and requires 2 to 8 hrs to reach peak serum levels. Therefore keeping these in mind, an attempt was made to prepare NLCs of Gliclazide which will provide controlled release, along with a concomitant improvement in solubility and dissolution profile of drug. Gliclazide loaded NLCs were produced by high shear homogenization coupled with ultrasonication technique using Precirol ATO 5 as solid lipid, Capryol 90 as liquid lipid, Tween 20 as surfactant and Transcutol HP as a cosurfactant. The NLCs were characterized for entrapment efficiency, particle size and in vitro drug release. The optimized batch was subjected to freeze drying using trehalose as cryoprotectant and the freeze dried powder was filled into hard gelatin capsule of suitable size. In vitro release studies of NLC capsules showed that Gliclazide exhibited an initial burst release followed by a sustained release of 88.46% compared to the marketed S.R. tablet which showed a slow and sustained release of 86.34% at the end of 24 hours.

Keywords: Nanostructured lipid carrier, Gliclazide, Sustained release.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More